Home › NCT06741527
Integrity Implant System Post Market Clinical Follow-Up Study
Recruiting
Post Market Confirmatory Interventional Clinical Study of the Integrity Implant System Used for Rotator Cuff Tear Augmentation
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
1. At least 18 years of age 2. Able (with assistance from LAR, if necessary) to understand the informed consent process, including regulatory requirements such as HIPAA authorization, and document informed consent prior to completion of any study-related procedures. 3. Able to complete all Patient Reported Outcome Measure (PROM) questionnaires. 4. Fully understands study requirements and able to return for all required follow-up visits and assessments. 5. Able to comply with all post-operative physician prescribed rehabilitation instructions. 6. Index shoulder rotator cuff tendon tear surgical access may be performed using mini-open, single-portal arthroscopic or multi-portal arthroscopic intervention 7. Meets all intended use and indications for use defined within the Integrity Implant System IFUs as applied to rotator cuff tendon tears. These include: Index shoulder rotator cuff tendon tear needs management and protection from injury Index shoulder has no substantial loss of tendon tissue Index shoulder rotator cuff tendon tear footprint allows approximation of soft tissue and fixation of the Integrity Implant to tendon tissue using an Integrity Tissue Tack Index shoulder rotator cuff tendon tear footprint allows fixation of the Integrity Implant to bone using the Integrity Bone Staple Exclusion Criteria The subject exclusion criteria are as follows: 1. Medical condition that in the PI's opinion would place the subject at risk or interfere with the study 2. Vulnerable population (prisoners, minors, pregnant women, mentally ill persons and the elderly or any person under any undue pressure from others to participate in the study) 3. Pregnant, breastfeeding, or plans to become pregnant during the study 4. History of poor compliance with medical treatment of any kind 5. Deemed contraindicated for MRI by the PI 6. Previous rotator cuff surgery (any type) on the index shoulder 7. Current instability of the index shoulder 8. Rotator cuff tendon tear is a Massive Cofield Classified Full-Thickness Tear (tear length \>5cm) 9. Chondromalacia of index shoulder ≥ Grade 3 10. Fatty infiltration of the index shoulder rotator cuff muscle ≥ Grade 3 11. Insulin dependent Type I Diabetes 12. History of heavy smoking (≥ 1 pack per day) within last 6-months 13. History of auto-immune or immunodeficiency disorders 14. Currently taking immunosuppression medication for other diseases (e.g., transplants or other inflammatory diseases) 15. Oral steroid use in the last 2-months or injectable steroid use in the last 3-months 16. History of cognitive or mental health status that interferes with study participation 17. Poor comprehension of English language 18. Meets one or more of the contraindications defined within the Integrity Implant System IFUs as applied to rotator cuff tendon tears. These include: 18.1 Rotator cuff tendon tear is deemed irreparable by the PI 18.2 Rotator cuff tendon tear repair requires replacement of damaged tendon 18.3 Rotator cuff tendon tear repair requires fixation of soft tissue to adjoining soft tissue 18.4 Rotator cuff tendon tear repair requires tendon strength reinforcement 18.5 Presence of infection 18.6 Any condition which would limit the ability or willingness to restrict activities or follow directions during the healing period 18.7 Hypersensitivity to any of the Integrity Implant System components 18.8 Inadequate soft tissue support for Integrity Tissue Tack fixation 18.9 Inadequate quality of bone for Integrity Bone Staple fixation
About the study
The study design is a prospective, multi-center, single-arm, non-randomized post market clinical follow-up study to confirm the performance, safety and clinical benefit of the Integrity Implant System when used for rotator cuff tear augmentation (with or without repair).
What is being tested
- Integrity Implant System (device)
Sponsor: Anika Therapeutics, Inc. · Participants: 150 · Started: Feb 1, 2025
Contact the study team
- Kara Mezger · Phone: 781-457-9000
- Jennifer Williams · Phone: 781-457-9000
Official record on ClinicalTrials.gov — NCT06741527
Locations in the U.S.
| Arizona | OrthoArizona, Gilbert |
| California | Premier Orthopaedic Trauma Specialists, PMC, Pomona |
| Florida | Foundation for Orthopaedic Research and Education, Tampa |
| Georgia | Harbin Clinic, Rome |
| Indiana | Central Indiana Orthopaedics, Fishers |
| Maryland | Towson Orthopaedic Associates/University of Maryland St. Joseph's Medical Center, Towson |
| New Jersey | Virtua Health, Marlton |
| South Carolina | Steadman Hawkins Clinic of the Carolinas, Greenville |
| Tennessee | Campbell Clinic, Germantown |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.